Multiple Myeloma Clinical Trials in Houston, Texas

25 studies are recruiting for multiple myeloma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

   This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   24 in total

   Run by

   Heidelberg Pharma AG

   See if you can join NCT04879043 on ClinicalTrials.gov

2. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

3. A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   22 in total

   Run by

   Celgene

   See if you can join NCT06988488 on ClinicalTrials.gov

4. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

5. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

7. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   71 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07266441 on ClinicalTrials.gov

8. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

   Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superio…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   139 in total

   Run by

   Pfizer

   See if you can join NCT05623020 on ClinicalTrials.gov

9. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

   The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Cancer Center Infusion, Houston, Texas

   Locations

   270 in total

   Run by

   Pfizer

   See if you can join NCT06152575 on ClinicalTrials.gov

10. Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

    Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06105554 on ClinicalTrials.gov

11. Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

    To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06207799 on ClinicalTrials.gov

12. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

    The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

    Stage

    Phase 1

    Ages

    12 to 80

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05092451 on ClinicalTrials.gov

13. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    19 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06121843 on ClinicalTrials.gov

14. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Oncology Consultants /ID# 268323, Houston, Texas

    Locations

    46 in total

    Run by

    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

15. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Houston, Texas

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07073547 on ClinicalTrials.gov

16. Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

    To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

    Stage

    Phase 2

    Ages

    18 to 72

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05776979 on ClinicalTrials.gov

17. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Houston Methodist Hospital, Houston, Texas

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

18. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    32 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

19. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

20. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Clinic, Houston, Texas

    Locations

    40 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT03761108 on ClinicalTrials.gov

21. Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

    This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05336383 on ClinicalTrials.gov

22. ATRA and Carfilzomib in Plasma Cell Myeloma Patients

    This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM), in patients considered refractory to proteasom…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Houston Methodist Neal Cancer Center, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT06536413 on ClinicalTrials.gov

23. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    MDACC, Houston, Texas

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

24. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    12 in total

    Run by

    Indapta Therapeutics, INC.

    See if you can join NCT06119685 on ClinicalTrials.gov

25. Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

    This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    2 in total

    Run by

    Pack Health

    See if you can join NCT05053607 on ClinicalTrials.gov